- The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ:SRNE) IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR)-T Cell therapy for relapsed or refractory multiple myeloma.
- DAR-T technology is readily adaptable to dozens of cancer targets, and Sorrento has developed a preclinical product pipeline with specific fully human antibodies discovered from Sorrento's G-MAB library.
- Sorrento expects to file additional IND applications now that the first DAR-T Phase 1 trial has been cleared to proceed by the FDA.
- Price Action: SRNE shares are up 2.98% at $8.47 during the market session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
